Physician profile
Randall Wright
NPI 1316035058
$22,715.97
in general payments reported to CMS, 2019-2025
72 companies · $6,640 in 2025
The $6,640 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,068 · 2020: $2,492 · 2021: $3,132 · 2022: $2,024 · 2023: $2,898 · 2024: $3,462 · 2025: $6,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,620 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,150 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,620.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,150.00 |
| Education | $230.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,091.64 | 2023-2025 | |
| Eisai INC. | $1,422.51 | 2019-2025 | |
| Abbvie INC. | $1,339.30 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,171.89 | 2019-2025 | |
| Lilly USA, LLC | $947.21 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Ucb, INC. | $917.37 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $860.74 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Sk Life Science, INC. | $811.91 | 2020-2025 | Xcopri |
| Biogen, INC. | $553.98 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Jazz Pharmaceuticals INC. | $536.74 | 2019-2025 | |
| Emd Serono, INC. | $493.80 | 2019-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $485.34 | 2020-2024 | Ingrezza, Ongentys |
| Inspire Medical Systems, INC. | $460.42 | 2024-2025 | Inspire |
| Sunovion Pharmaceuticals INC. | $444.19 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $414.32 | 2024-2025 | Rexulti |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $408.67 | 2019-2025 | Vyepti |
| Allergan, INC. | $372.52 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $364.64 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $344.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $330.17 | 2021-2023 | Andexxa |
| Genentech USA, INC. | $301.37 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Adamas Pharmaceuticals, INC. | $298.85 | 2020-2021 | |
| Genzyme Corporation | $296.04 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $290.19 | 2022 | |
| Amgen INC. | $285.20 | 2019-2025 | Aimovig, Uplizna |
| Mdd US Operations, LLC | $262.07 | 2019-2020 | |
| Argenx US, INC. | $255.75 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Harmony Biosciences LLC | $255.41 | 2020-2025 | Wakix |
| Averitas Pharma INC. | $239.16 | 2023-2025 | Qutenza |
| Abbott Laboratories | $223.39 | 2021-2025 | Infinity, Proclaim |
| Acadia Pharmaceuticals INC | $187.11 | 2019-2025 | Nuplazid |
| Tg Therapeutics, INC. | $184.55 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $181.50 | 2019-2025 | Ultomiris |
| Novo Nordisk INC | $180.45 | 2020-2022 | |
| Boston Scientific Corporation | $137.66 | 2022-2024 | Vercise |
| Ge Healthcare | $133.23 | 2019-2024 | |
| Itamar Medical INC | $124.57 | 2025 | Watchpatone |
| Medtronic, INC. | $123.80 | 2025 | Linq II, Percept PC Brainsense |
| Neurelis, INC. | $119.20 | 2020-2023 | Valtoco |
| Livanova USA, INC. | $116.99 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Upsher-Smith Laboratories LLC | $112.38 | 2019-2021 | |
| Nevro Corp. | $109.19 | 2019 | |
| Grt US Holding, INC. | $109.05 | 2020-2022 | |
| Catalyst Pharmaceuticals, INC. | $95.81 | 2022-2024 | |
| Axsome Therapeutics, INC. | $89.15 | 2025 | Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $85.33 | 2023-2024 | Hyqvia, Gammagard |
| Sumitomo Pharma America, INC. | $83.02 | 2023-2024 | Aptiom |
| Assertio Therapeutics, INC. | $82.88 | 2019-2020 | |
| Greenwich Biosciences, INC. | $74.86 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $74.59 | 2022-2025 | Crexont |
| Horizon Therapeutics Plc | $71.90 | 2021-2022 | |
| Aquestive Therapeutics, INC. | $68.66 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $67.27 | 2024 | Xeomin |
| Avadel Cns Pharmaceuticals, LLC | $53.67 | 2024-2025 | Lumryz |
| Celgene Corporation | $51.58 | 2025 | Zeposia |
| Azurity Pharmaceuticals, INC. | $49.37 | 2024-2025 | Horizant |
| Corium, LLC | $47.05 | 2022-2023 | Adlarity |
| Aucta Pharmaceuticals, INC. | $46.95 | 2024 | Motpoly Xr |
| Depuy Synthes Sales INC. | $42.88 | 2021 | |
| Impel Pharmaceuticals INC. | $40.72 | 2022-2023 | Trudhesa |
| Merz North America, INC. | $39.06 | 2019 | |
| Sanofi-Aventis U.S. LLC | $33.28 | 2020-2021 | |
| Insightec,INC | $29.69 | 2024 | Exablate |
| Convatec INC. | $28.71 | 2022 | |
| Alnylam Pharmaceuticals INC. | $28.39 | 2022 | |
| Almatica Pharma LLC | $27.47 | 2021 | |
| Arbor Pharmaceuticals, INC. | $27.10 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.32 | 2022 | |
| Microtransponder, INC. | $16.85 | 2023 | |
| Impel Pharmaceuticals LLC | $16.03 | 2025 | Trudhesa |
| Janssen Pharmaceuticals, INC | $14.51 | 2022 | |
| Grifols USA, LLC | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.